Comments

Invesco Biotechnology & Genome ETF Stock Price, Quotes and Forecasts

PBEARCA
Logo brought to you by Benzinga Data
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$63.94
-0.80-1.24%
At close: -

Overview

NewsHoldingsDividendsShort Interest
Edge Rankings

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Sector
Healthcare
Region
US
AUM
226.70M
Fund Score

Invesco Biotechnology & Genome ETF Price, Quotes and Forecasts | ARCA:PBE | Benzinga

Explore Invesco Biotechnology & Genome ETF stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for PBE.

Open$63.78
High$64.29
52 Wk High$72.84
AUM226.70M
Dividend$0.06
Ex-Div DateJun 24, 2024
Volume2.7K
Market Cap$26.27B
Mgmt Fee0.5%
P/E Ratio21.74
Prev. Close$64.75
Low$63.78
52 Wk Low$54.52
Shares Out4.04M
Yield0.09%
Div. FreqQuarterly
Avg. Volume Daily12.08K
Beta0.81
Avg. Expense Ratio0.58%
P/B Ratio3.74

Recent News

Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention
U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of the abortion pill mifepristone. 
Vandana Singh
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules
A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug.
Vandana Singh
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this week.
Vandana Singh

FAQ

Q

How do I buy Invesco Biotechnology & Genome ETF (PBE) stock?

A

You can purchase shares of Invesco Biotechnology & Genome ETF (ARCA:PBE) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Invesco Biotechnology & Genome ETF (PBE) competitors?

A

There are no as such competitors for Invesco Biotechnology & Genome ETF.

Q

What is the forecast, or price target, for Invesco Biotechnology & Genome ETF (PBE) stock?

A

There is no analysis for Invesco Biotechnology & Genome ETF to provide a consensus price target.

Q

What is the current price for Invesco Biotechnology & Genome ETF (PBE)?

A

The stock price for Invesco Biotechnology & Genome ETF (ARCA: PBE) is $62.21 last updated April 1, 2025 at 7:44 AM EDT.

Q

Does Invesco Biotechnology & Genome ETF (PBE) pay a dividend?

A

A quarterly cash dividend of 0.00 per share of Class A Common Stock. The quarterly cash dividend was payable on September 28, 2018 to stockholders of record on September 24, 2018.

Q

When is Invesco Biotechnology & Genome ETF (ARCA:PBE) reporting earnings?

A

Invesco Biotechnology & Genome ETF does not have any upcoming earnings scheduled.

Q

Is Invesco Biotechnology & Genome ETF (PBE) going to split?

A

There is no upcoming split for Invesco Biotechnology & Genome ETF.

Open$63.78
High$64.29
52 Wk High$72.84
AUM226.70M
Dividend$0.06
Ex-Div DateJun 24, 2024
Volume2.7K
Market Cap$26.27B
Mgmt Fee0.5%
P/E Ratio21.74
Prev. Close$64.75
Low$63.78
52 Wk Low$54.52
Shares Out4.04M
Yield0.09%
Div. FreqQuarterly
Avg. Volume Daily12.08K
Beta0.81
Avg. Expense Ratio0.58%
P/B Ratio3.74
About Invesco Capital Management LLC
Sector
N/A
Industry
N/A
ETF Details
SectorHealthcare
CategoryMid Performer-Mid Growth
Investment StyleMid Cap Growth
Fund InceptionJun 23, 2005
Managers
Tony Seisser
Michael Jeanette
Peter Hubbard
Pratik Doshi
DefinitionMost of the stocks in this equity fund have average financial performance and average growth potential
Investment Policy
The Fund generally will invest at least 90% of its total assets in securities that comprise the Underlying Index. The Underlying Index is composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, and are companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research.
Top ETF Holdings
SymbolNameShare %
GILDGilead Sciences Inc5.25%
ILMNIllumina, Inc.4.57%
INCYIncyte Corp.5.20%
BMRNBiomarin Pharmaceutica...5.09%
VRTXVertex Pharmaceuticals...5.05%
AMGNAmgen Inc.4.86%
REGNRegeneron Pharmaceutic...3.61%
NBIXNeurocrine Biosciences...5.65%
IONSIonis Pharmaceuticals ...3.24%
HALOHalozyme Therapeutics ...3.51%
NTRANatera Inc5.38%
BIIBBiogen Inc.4.81%
UTHRUnited Therapeutics Co...4.75%
AXSMAxsome Therapeutics, I...3.71%
DURpi International Hold...3.60%
PTGXProtagonist Therapeuti...3.93%
TGTXTg Therapeutics Inc Co...4.54%
BCRXBioCryst Pharmaceutica...3.76%

Connect With Us

instagramlinkedinyoutube

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2025 Benzinga | All Rights Reserved